{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:01:10Z","timestamp":1792976470011,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105180","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:33:44Z","timestamp":1770222824000},"page":"105180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"220","author":[{"given":"Olesya","family":"Kuznetsova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Battaiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Malvezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gervaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Alessandra","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Fedyanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Tryakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105180_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105180_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102683","article-title":"The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: a systematic review","volume":"124","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105180_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105180_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104511","article-title":"Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105180_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105491","article-title":"Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105180_bib6","article-title":"Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial","author":"Ciardiello","year":"2025","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105180_bib7","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105180_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105180_bib9","article-title":"Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO","author":"Cirac\u00ec","year":"2025","journal-title":"Ann. Oncol."},{"issue":"10395","key":"10.1016\/j.critrevonc.2026.105180_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.critrevonc.2026.105180_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105180_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303)","author":"Hecht","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105180_bib13","first-page":"237","author":"Jadad scale for reporting randomized controlled trials","year":"2005","journal-title":"Evid. -Based Obstet. Anesth."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105180_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105180_bib15","first-page":"S1","article-title":"Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): final results of the phase II randomized CITRIC trial","volume":"36","author":"Montagut","year":"2025","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105180_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","article-title":"Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer","volume":"9","author":"Napolitano","year":"2023","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105180_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.34632","article-title":"Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer","volume":"153","author":"Napolitano","year":"2023","journal-title":"Int J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105180_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105180_bib19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105180_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105180_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105180_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00037","article-title":"Negative ultraselection of patients with RAS\/BRAF Wild-Type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy","author":"Randon","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105180_bib23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients","volume":"23","author":"Santini","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105180_bib24","first-page":"S433","article-title":"Third line rechallenge with cetuximab and irinotecan (CITRIC)","volume":"35","author":"Santos Vivas","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105180_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105180_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41698-023-00353-4","article-title":"Survival improvement for patients with metastatic colorectal cancer over twenty years","volume":"7","author":"Zeineddine","year":"2023","journal-title":"npj Precis Onc"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:58:02Z","timestamp":1776974282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S1040842826000673"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105180","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105180"}}